Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of HBAI20 Hepatitis B Vaccine in Naive Adults and Non-responders

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* In good health as determined by the outcome of medical history, physical examination screening/baseline labs and clinical judgment of the clinical investigator~* Age 18 to 59 years, inclusive at the time of enrolment~* Willing and able to adhere to the study regimen~* Having a signed informed consent form~Non-responders:~- Documented non-responders: Subjects with documented two cycles of Hepatitis B vaccination (total of 6 vaccinations) and titer analysis that show that they have not developed the Hepatitis B antibody titer recommended after standard vaccination: anti-HBsAg antibody titer higher to 10mIU/ml.~Exclusion Criteria:~* Any infectious disease at the time of screening and/or enrolment~* Positive HIV, Hepatitis B virus or Hepatitis C virus serology~* Positive anti-IL-2 antibody titer~* Known or suspected immune deficiency~* Known or suspected disease that influences the immune system including chronic allergies that require frequent anti-allergy medication, cancer and transplantation recipients~* Known or suspected allergy to any of the vaccine components.~* Dialysis patient~* History of unusual or severe reactions to any previous vaccination~* History of any neurologic disorder, including epilepsy and autism~* Use of medication that influences the immune system (immune suppressive treatment)~* Any vaccination within 3 months before screening~* Blood donation within 1 month before screening~* Administration of plasma (incl. immunoglobulins) or blood products within 12 months before screening~* Participation in another clinical trial within 3 months before screening~* Abnormal pre-treatment laboratory parameters which are clinically relevant according to the investigator~* Bleeding disorders, or use of medication for bleeding disorders, and use of anti-coagulants~* Female subjects planning to become pregnant or breastfeeding babies until visit 7~* Females: positive urine pregnancy test. Urine test positive at screening date or positive urine pregnancy test on the day of vaccination~* Excessive alcohol or controlled drug use - More than 2 alcohol measures per day (one alcohol measure is a beer (250ml) or one glass of wine (125ml) or one strong measure (35ml) or one port/sherry (75ml)). Regular use of controlled drugs~Exclusion criterion for Hepatitis B naïve subjects (groups 1 and 2):~- Previous vaccination with Hepatitis B vaccine~Exclusion criterion for non-responders (group 3):~- Any Hepatitis B vaccination in the last 6 months~Temporary exclusion criterion for vaccination~- Ear temperature \> 38.4°C will lead to postponement of participation and vaccination. Screening may continue when the temperature has normalized.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 59 Years
- Healthy Volunteers: t

Study Arms:
- HB vaccine naive - HBVaxPro (Type: ACTIVE_COMPARATOR): Subjects have never been vaccinated with a Hepatitis B vaccine. Subjects are vaccinated with Hepatitis B vaccine HBVaxPro-10ug at day 0, 30, and 180.
- HB vaccine naive - HBAI20 (Type: EXPERIMENTAL): Subjects have never been vaccinated with a Hepatitis B vaccine. Subjects are vaccinated with Hepatitis B vaccine HBAI20 at day 0 and 30, and Hepatitis B vaccine HBVaxPro-10ug at day 180.
- Non-responders - HBAI20 (Type: EXPERIMENTAL): Subjects have been vaccinated 6 times with a Hepatitis B vaccine without developing a protective immune response, measured as anti Hepatitis B surface antigen antibodies, superior to 10mIU/ml.~Subjects are vaccinated with Hepatitis B vaccine HBAI20 at day 0 and 30, and Hepatitis B vaccine HBVaxPro-10ug at day 180.

Based on this trial design, predict the completion outcome and termination type (if applicable).